The facts on small-cell lung cancer, or SCLC, and non-small-cell lung cancer, or NSCLC, like symptoms, prognosis, treatment, and recovery.

When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

Non-small-cell lung cancer (NSCLC) is the most common form of lung cancer. Early NSCLC is when your disease is in its earliest stages, or stages I-II. That means that your lung tumor has grown and ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor.

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

A small cell lung cancer (SCLC) misdiagnosis is possible. This can occur because of challenges during the diagnostic tests and because SCLC may share symptoms and causes similar to other ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...